HnRNP L and L-like cooperate in multiple-exon regulation of CD45 alternative splicing - PubMed (original) (raw)
HnRNP L and L-like cooperate in multiple-exon regulation of CD45 alternative splicing
Marco Preussner et al. Nucleic Acids Res. 2012 Jul.
Abstract
CD45 encodes a trans-membrane protein-tyrosine phosphatase expressed in diverse cells of the immune system. By combinatorial use of three variable exons 4-6, isoforms are generated that differ in their extracellular domain, thereby modulating phosphatase activity and immune response. Alternative splicing of these CD45 exons involves two heterogeneous ribonucleoproteins, hnRNP L and its cell-type specific paralog hnRNP L-like (LL). To address the complex combinatorial splicing of exons 4-6, we investigated hnRNP L/LL protein expression in human B-cells in relation to CD45 splicing patterns, applying RNA-Seq. In addition, mutational and RNA-binding analyses were carried out in HeLa cells. We conclude that hnRNP LL functions as the major CD45 splicing repressor, with two CA elements in exon 6 as its primary target. In exon 4, one element is targeted by both hnRNP L and LL. In contrast, exon 5 was never repressed on its own and only co-regulated with exons 4 and 6. Stable L/LL interaction requires CD45 RNA, specifically exons 4 and 6. We propose a novel model of combinatorial alternative splicing: HnRNP L and LL cooperate on the CD45 pre-mRNA, bridging exons 4 and 6 and looping out exon 5, thereby achieving full repression of the three variable exons.
Figures
Figure 1.
HnRNP LL is differentially expressed in B-cell lines and regulates CD45 alternative splicing. (A) High LL expression correlates with the plasma cell stage of B-cell development, while L is expressed at similar levels in most of the B-cell lines tested (names of cell lines above the lanes). Lysates from B-cell lines derived from early, mature or activated stages of B-cell development [left panel: pre B-cell stage (pre), lymphoblastoid cell lines (LCL) and Burkitt lymphoma B-cell lines (BL), as indicated below] and from plasma cell-derived B-cell lines (right panel: myeloma cell lines) were analyzed by western blot for L/LL (GAPDH as a loading control). (B) CD45 alternative exon repression correlates with LL expression levels. CD45 alternative splicing analysis by RT-PCR, comparing two different B-cell lines (Burkitt lymphoma line DG75, myeloma cell line U-266). Primer pairs (CD45 ex3–9, 3–5 and 5–7) and products (CD45 splice forms R456, R56, R5, R0; exons 4 and 6 inclusion/skipping forms; constitutive ex8–9 product) are labeled on the side. M, DNA size markers. Below, the expression of LL, L and γ-tubulin were detected by western blotting. (C) HnRNP LL overexpression is sufficient for CD45 exons 4–6 skipping and the generation of the R0 form. DG75 cells were transfected with increasing amounts of LL-V5-His plasmid (0.05, 0.2, 0.5 or 2 µg), or as a control, GFP (1 µg). Total RNA was analyzed by RT-PCR (top) for CD45 alternative splicing [products and primer pairs indicated on the right, as in panel (B)]. M, DNA size markers. Below, LL overexpression was assessed by western blotting, with GAPDH as a control.
Figure 2.
RNA-Seq analysis of CD45 alternative splicing in DG75 B-cells. LL (or as a control, GFP) was overexpressed in DG75 B-cells, followed by RNA-Seq analysis of total RNA. On the top, the read densities across the CD45 exons 3–7 region are represented, comparing GFP control (in blue) and LL overexpression (in red). The numbers below indicate the respective read densities of exons 3–7. In the middle, the ratios of LL/GFP exon read densities, normalized to the constitutive exons 3 and 7, are given, below, the exon–intron structure. The bottom part summarizes the absolute junction read counts, with the arrows indicating changes in a particular splice event after LL overexpression (↑ increase; ↓ decrease).
Figure 3.
CD45 alternative splicing of a minigene in HeLa cells: specific repression of CD45 alternative exons 4–6 by hnRNP L and LL. (A) L (ΔL), LL (ΔLL), or both of them (ΔL + ΔLL) were RNAi-downregulated in HeLa cells, including a control luciferase knockdown (Δluc), as confirmed by western blot for L, LL and GAPDH. (B) Following knockdown, the CD45 WT minigene was transfected, and CD45 alternative splicing was assayed by RT-PCR (primer pairs indicated above the lanes, and schematically shown below). The RT-PCR products indicative of the R456, R45, R5 and R0 forms (for primer pair 3–7), or for the inclusion/skipping-products (for primer pairs 5–7, 3–5 and 4–6; see brackets) are marked on the left. All lanes come from a single gel, but were rearranged for clarity. M, DNA size markers. Below, the repressor activities of L versus LL for CD45 exons 4–6, as well as for the entire exons 4–6 unit are summarized (++ strong; + weak; − not significant).
Figure 4.
Mutational analysis of CD45 silencer elements in exons 4 and 6. (A) CD45 WT minigenes and mutant derivatives [as indicated above the lanes; see panel (B) for schematic representations] were transfected in HeLa cells, followed by RT-PCR with primers against CD45 exons 3 and 7 (products represented on the right). For CD45 WT and mutants 4/5′CA, 6/m + 3′CA and 4/5′CA + 6/m + 3′CA, additional cotransfections were done with GFP (as control), with FLAG-L or FLAG-LL (as indicated above the lanes), followed by RT-PCR assays with exons 3–7 or 4–6 primer pairs (as indicated). The asterisk marks an unspecific PCR product, which could not be identified. M, DNA size markers. (B) Summary of CD45 mutant minigenes used (the position of mutations marked by thick vertical lines). The mutated nucleotide positions in exons 4 and 6 are specified below, in each case with the CA elements in bold letters and the mutations underlined. Spliced CD45 isoforms are represented on the right side, with single and double arrows indicating changes compared to wild-type.
Figure 5.
In vitro binding of hnRNP L and LL to CD45 exons 4–6. (A) RNA binding of hnRNP L/LL correlates with repressor activity. Equimolar amounts of 3′-biotinylated RNAs, containing wild-type or mutant versions of each variable exon (as indicated above the lanes and schematically on the right), were prebound to Neutravidin agarose, followed by incubation in HeLa nuclear extract, washing at 100 mM KCl, release of bound protein and western-blot analysis for LL, L and, as a control, GAPDH. For comparison, nuclear extract input was analyzed in parallel (lanes 1; 20% for LL and GAPDH; 5% for L). Quantitation of L/LL pulldown is given below each lane (in % relative to the input, including SDs). (B) An RNA containing CD45 exons 4-5-6 in cis stabilizes hnRNP L binding, depending on exons 4 and 6. As described in panel (A), pre-mRNAs, containing either the wild-type sequence (exons 4-5-6) or a mutant derivative, combining silencer mutations in exons 4 and 6 (exons 4*-5-6*), were compared with single-exons 5 and 6 RNAs for L versus LL binding in nuclear extract (lanes 1–14). Complex stability was tested by washing under different salt conditions (as indicated on top: 100–300 mM KCl). In addition, L/LL binding to mutant exon 4-5-6 derivatives were compared, in which one of the three exons was replaced by DUP sequence (DUP-ex4, -ex5 and -ex6; lanes 15–18).
Figure 6.
CD45 RNA-dependent interaction of hnRNP L and LL in vivo. (A) Schematic of CD45 minigenes and experimental protocol. (B) Interaction depends on CD45 RNA expression: HeLa cells were transfected with either FLAG-LL alone (lanes 1 and 2), or in combination with the CD45 WT minigene (lanes 3–6). As controls, CD45 WT was cotransfected with GFP (lanes 7–9), or FLAG-LL with GFP (lanes 10–12). Lysates were prepared without or with RNase treatment (as indicated), followed by FLAG pulldown assays. Coprecipitated L was detected by western blot, comparing input (lanes i; 2.5%) and bound material (lanes b; 20%), in parallel with LL, FLAG tag and loading control GAPDH. (C) Interaction depends on exons 4 and 6: Additional FLAG pulldown assays were performed after cotransfections of FLAG-LL and CD45 WT (lanes 13 and 14) or mutant minigenes carrying DUP-substituted exons 4–6 (DUP-ex4, -ex5, -ex6; lanes 15–20).
Figure 7.
Model of CD45 alternative splicing of variable exons 4/5/6, determined by combined activities of L/LL paralogs (for details, see ‘Discussion’ section).
Similar articles
- A cell-based screen for splicing regulators identifies hnRNP LL as a distinct signal-induced repressor of CD45 variable exon 4.
Topp JD, Jackson J, Melton AA, Lynch KW. Topp JD, et al. RNA. 2008 Oct;14(10):2038-49. doi: 10.1261/rna.1212008. Epub 2008 Aug 21. RNA. 2008. PMID: 18719244 Free PMC article. - HnRNP L represses exon splicing via a regulated exonic splicing silencer.
Rothrock CR, House AE, Lynch KW. Rothrock CR, et al. EMBO J. 2005 Aug 3;24(15):2792-802. doi: 10.1038/sj.emboj.7600745. Epub 2005 Jul 7. EMBO J. 2005. PMID: 16001081 Free PMC article. - Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M.
Dery KJ, Gaur S, Gencheva M, Yen Y, Shively JE, Gaur RK. Dery KJ, et al. J Biol Chem. 2011 May 6;286(18):16039-51. doi: 10.1074/jbc.M110.204057. Epub 2011 Mar 11. J Biol Chem. 2011. PMID: 21398516 Free PMC article. - hnRNP L and hnRNP A1 induce extended U1 snRNA interactions with an exon to repress spliceosome assembly.
Chiou NT, Shankarling G, Lynch KW. Chiou NT, et al. Mol Cell. 2013 Mar 7;49(5):972-82. doi: 10.1016/j.molcel.2012.12.025. Epub 2013 Feb 7. Mol Cell. 2013. PMID: 23394998 Free PMC article. - Differential expression of CD45 isoforms is controlled by the combined activity of basal and inducible splicing-regulatory elements in each of the variable exons.
Tong A, Nguyen J, Lynch KW. Tong A, et al. J Biol Chem. 2005 Nov 18;280(46):38297-304. doi: 10.1074/jbc.M508123200. Epub 2005 Sep 19. J Biol Chem. 2005. PMID: 16172127
Cited by
- Dnmt3bas coordinates transcriptional induction and alternative exon inclusion to promote catalytically active Dnmt3b expression.
Dar MS, Mensah IK, He M, McGovern S, Sohal IS, Whitlock HC, Bippus NE, Ceminsky M, Emerson ML, Tan HJ, Hall MC, Gowher H. Dar MS, et al. Cell Rep. 2023 Jun 27;42(6):112587. doi: 10.1016/j.celrep.2023.112587. Epub 2023 Jun 8. Cell Rep. 2023. PMID: 37294637 Free PMC article. - Recent insights into the role of Akt in CD4 T-cell activation and differentiation: alternative splicing and beyond.
White TLA, Jin Y, Gable MJ, Morel PA. White TLA, et al. Immunometabolism (Cobham). 2023 Jan 23;5(1):e00015. doi: 10.1097/IN9.0000000000000015. eCollection 2023 Jan. Immunometabolism (Cobham). 2023. PMID: 36710922 Free PMC article. Review. - The influence of three-dimensional structure on naïve T cell homeostasis and aging.
Lambert S, Cao W, Zhang H, Colville A, Liu JY, Weyand CM, Goronzy JJ, Gustafson CE. Lambert S, et al. Front Aging. 2022 Nov 7;3:1045648. doi: 10.3389/fragi.2022.1045648. eCollection 2022. Front Aging. 2022. PMID: 36419548 Free PMC article. - Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics.
Peng Q, Zhou Y, Oyang L, Wu N, Tang Y, Su M, Luo X, Wang Y, Sheng X, Ma J, Liao Q. Peng Q, et al. Mol Ther. 2022 Mar 2;30(3):1018-1035. doi: 10.1016/j.ymthe.2021.11.010. Epub 2021 Nov 15. Mol Ther. 2022. PMID: 34793975 Free PMC article. Review. - Structural basis of the interaction between SETD2 methyltransferase and hnRNP L paralogs for governing co-transcriptional splicing.
Bhattacharya S, Wang S, Reddy D, Shen S, Zhang Y, Zhang N, Li H, Washburn MP, Florens L, Shi Y, Workman JL, Li F. Bhattacharya S, et al. Nat Commun. 2021 Nov 8;12(1):6452. doi: 10.1038/s41467-021-26799-3. Nat Commun. 2021. PMID: 34750379 Free PMC article.
References
- Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136:701–718. - PubMed
- Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008;40:1413–1415. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous